In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Coronary Artery Disease
Interventions
DRUG

Ticagrelor 180mg

The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.

DRUG

Ticagrelor 90mg

The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.

Trial Locations (1)

32209

Dominick Angiolillo, Jacksonville

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

The Medicines Company

INDUSTRY

lead

University of Florida

OTHER